Kan Chen
Impact in
- Hepatology top 1%
- Liver physiology and pathology
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Diseases and Immunity
- Aging top 2%
Papers in
- Hepatology 30
- Liver physiology and pathology 12
- Hepatocellular Carcinoma Treatment and Prognosis 9
- Liver Diseases and Immunity 9
- Pharmacology 16
- Drug-Induced Hepatotoxicity and Protection 14
- Co-authors
- Jingjing Li (53 shared papers)郭传勇 (52 shared papers)Weiqi Dai (43 shared papers)Sainan Li (39 shared papers)Yujing Xia (40 shared papers)Jie Lu (39 shared papers)Yingqun Zhou (35 shared papers)Jiao Feng (30 shared papers)
- Journals
- Marine Drugs (9 papers)Drug Design Development and Therapy (7 papers)Oncotarget (6 papers)PLoS ONE (5 papers)Blood (5 papers)
- Partner nations
- ChinaUnited StatesNetherlands
In The Last Decade
Kan Chen
181 papers receiving 6.8k citations
Kan Chen's Hit Papers
Peers
Comparison fields: 5 of 140
- Hepatology 967
- Aging 99
- Cancer Research 681
- Drug Discovery 10
- Pharmacology 333
Countries citing papers authored by Kan Chen
This map shows the geographic impact of Kan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kan Chen more than expected).
Fields of papers citing papers by Kan Chen
This network shows the impact of papers produced by Kan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kan Chen. The network helps show where Kan Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Kan Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 184 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 252 | |
| 2 | 2017 | 228 | |
| 3 | 2020 | 191 | |
| 4 | 2020 | 178 | |
| 5 | 2012 | 177 | |
| 6 | 2008 | 173 | |
| 7 | 2019 | 163 | |
| 8 | 2019 | 146 | |
| 9 | 2017 | 144 | |
| 10 | 2020 | 130 | |
| 11 | 2015 | 127 | |
| 12 | 2015 | 124 | |
| 13 | 2015 | 114 | |
| 14 | 2011 | 113 | |
| 15 | 2014 | 109 | |
| 16 | 2016 | 101 | |
| 17 | 2011 | 100 | |
| 18 | 2017 | 97 | |
| 19 | 2014 | 95 | |
| 20 | 2019 | 91 |
About Kan Chen
Kan Chen is a scholar working on Hepatology, Pharmacology, Cancer Research, Oncology and Genetics, having authored 184 papers that have together received 6.9k indexed citations. Recurring topics across this work include Drug-Induced Hepatotoxicity and Protection (14 papers), Virus-based gene therapy research (12 papers), Liver physiology and pathology (12 papers), Organ Transplantation Techniques and Outcomes (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Liver Diseases and Immunity (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Liver Disease Diagnosis and Treatment (7 papers). The work is most often cited by research in Hepatology (967 citations), Aging (99 citations), Cancer Research (681 citations), Drug Discovery (10 citations) and Pharmacology (333 citations). Kan Chen has collaborated with scholars based in China, United States and Netherlands. Frequent co-authors include Jingjing Li, 郭传勇, Weiqi Dai, Sainan Li, Yujing Xia, Jie Lu, Yingqun Zhou, Jiao Feng, Liwei Wu and Ling Xu. Their work appears in journals such as Marine Drugs, Drug Design Development and Therapy, Oncotarget, PLoS ONE and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.